25 XP   0   0   10

SkinBioTherapeutics PLC
Buy, Hold or Sell?

Let's analyse Skinbiotherapeutics together

PenkeI guess you are interested in SkinBioTherapeutics PLC. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of SkinBioTherapeutics PLC. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about SkinBioTherapeutics PLC

I send you an email if I find something interesting about SkinBioTherapeutics PLC.

Quick analysis of Skinbiotherapeutics (30 sec.)










What can you expect buying and holding a share of Skinbiotherapeutics? (30 sec.)

How much money do you get?

How much money do you get?
p0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
p1.03
Expected worth in 1 year
p0.04
How sure are you?
50.0%

+ What do you gain per year?

Total Gains per Share
p-1.00
Return On Investment
-10.8%

For what price can you sell your share?

Current Price per Share
p9.25
Expected price per share
p7 - p14.00
How sure are you?
50%

1. Valuation of Skinbiotherapeutics (5 min.)




Live pricePrice per Share (EOD)

p9.25

Intrinsic Value Per Share

p-21.01 - p-18.22

Total Value Per Share

p-19.98 - p-17.19

2. Growth of Skinbiotherapeutics (5 min.)




Is Skinbiotherapeutics growing?

Current yearPrevious yearGrowGrow %
How rich?$2.4m$3m-$598.6k-24.1%

How much money is Skinbiotherapeutics making?

Current yearPrevious yearGrowGrow %
Making money-$3.5m-$3.4m-$53k-1.5%
Net Profit Margin-2,146.9%-3,735.4%--

How much money comes from the company's main activities?

3. Financial Health of Skinbiotherapeutics (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

What can you expect buying and holding a share of Skinbiotherapeutics? (5 min.)

Welcome investor! Skinbiotherapeutics's management wants to use your money to grow the business. In return you get a share of Skinbiotherapeutics.

What can you expect buying and holding a share of Skinbiotherapeutics?

First you should know what it really means to hold a share of Skinbiotherapeutics. And how you can make/lose money.

Speculation

The Price per Share of Skinbiotherapeutics is p9.25. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Skinbiotherapeutics.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Skinbiotherapeutics, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is p1.03. Based on the TTM, the Book Value Change Per Share is p-0.25 per quarter. Based on the YOY, the Book Value Change Per Share is p-1.42 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is p0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Skinbiotherapeutics.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 p% of Price per Sharep% of Price per Sharep% of Price per Sharep% of Price per Sharep% of Price per Share
Usd Eps-0.02-0.2%-0.02-0.2%-0.02-0.2%-0.01-0.1%-0.01-0.1%
Usd Book Value Change Per Share0.000.0%0.000.0%-0.02-0.2%0.000.0%0.000.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.000.0%0.000.0%-0.02-0.2%0.000.0%0.000.0%
Usd Price Per Share0.16-0.16-0.25-0.33-0.25-
Price to Earnings Ratio-8.50--8.50--15.45--33.00--28.47-
Price-to-Total Gains Ratio-50.16--50.16--14.25-12.00-4.22-
Price to Book Ratio12.08-12.08-15.77-14.97-10.93-
Price-to-Total Gains Ratio-50.16--50.16--14.25-12.00-4.22-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.11526425
Number of shares8675
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (8675 shares)-26.94-16.22
Gains per Year (8675 shares)-107.75-64.86
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-108-1180-65-75
20-216-2260-130-140
30-323-3340-195-205
40-431-4420-259-270
50-539-5500-324-335
60-647-6580-389-400
70-754-7660-454-465
80-862-8740-519-530
90-970-9820-584-595
100-1078-10900-649-660

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.08.00.00.0%0.08.00.00.0%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%4.04.00.050.0%4.04.00.050.0%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.08.00.0%0.00.08.00.0%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%4.04.00.050.0%4.04.00.050.0%

Fundamentals of Skinbiotherapeutics

About SkinBioTherapeutics PLC

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study. It serves cosmetic skincare, food supplements, medical skin care, infection control, and pharmaceutical skincare markets. The company was formerly known as Skinbiotix Ltd and changed its name to SkinBioTherapeutics plc in December 2016. SkinBioTherapeutics plc was incorporated in 2015 and is based in Newcastle upon Tyne, the United Kingdom.

Fundamental data was last updated by Penke on 2024-04-09 08:51:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of SkinBioTherapeutics PLC.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Skinbiotherapeutics earns for each 1 of revenue.

  • Above 10% is considered healthy but always compare Skinbiotherapeutics to the Biotechnology industry mean.
  • A Net Profit Margin of -2,146.9% means that -21.47 for each 1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of SkinBioTherapeutics PLC:

  • The MRQ is -2,146.9%. The company is making a huge loss. -2
  • The TTM is -2,146.9%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-2,146.9%TTM-2,146.9%0.0%
TTM-2,146.9%YOY-3,735.4%+1,588.5%
TTM-2,146.9%5Y-1,176.5%-970.5%
5Y-1,176.5%10Y-752.8%-423.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2,146.9%-207.2%-1,939.7%
TTM-2,146.9%-216.8%-1,930.1%
YOY-3,735.4%-282.3%-3,453.1%
5Y-1,176.5%-436.8%-739.7%
10Y-752.8%-597.3%-155.5%
1.1.2. Return on Assets

Shows how efficient Skinbiotherapeutics is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Skinbiotherapeutics to the Biotechnology industry mean.
  • -109.3% Return on Assets means that Skinbiotherapeutics generated -1.09 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of SkinBioTherapeutics PLC:

  • The MRQ is -109.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -109.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-109.3%TTM-109.3%0.0%
TTM-109.3%YOY-90.5%-18.8%
TTM-109.3%5Y-61.6%-47.7%
5Y-61.6%10Y-43.4%-18.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-109.3%-13.3%-96.0%
TTM-109.3%-12.8%-96.5%
YOY-90.5%-11.6%-78.9%
5Y-61.6%-13.8%-47.8%
10Y-43.4%-15.6%-27.8%
1.1.3. Return on Equity

Shows how efficient Skinbiotherapeutics is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Skinbiotherapeutics to the Biotechnology industry mean.
  • -142.1% Return on Equity means Skinbiotherapeutics generated -1.42 for each 1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of SkinBioTherapeutics PLC:

  • The MRQ is -142.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -142.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-142.1%TTM-142.1%0.0%
TTM-142.1%YOY-112.8%-29.3%
TTM-142.1%5Y-74.7%-67.4%
5Y-74.7%10Y-51.8%-22.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-142.1%-16.9%-125.2%
TTM-142.1%-16.1%-126.0%
YOY-112.8%-14.9%-97.9%
5Y-74.7%-19.3%-55.4%
10Y-51.8%-20.1%-31.7%

1.2. Operating Efficiency of SkinBioTherapeutics PLC.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Skinbiotherapeutics is operating .

  • Measures how much profit Skinbiotherapeutics makes for each 1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Skinbiotherapeutics to the Biotechnology industry mean.
  • An Operating Margin of -2,271.3% means the company generated -22.71  for each 1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of SkinBioTherapeutics PLC:

  • The MRQ is -2,271.3%. The company is operating very inefficient. -2
  • The TTM is -2,271.3%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-2,271.3%TTM-2,271.3%0.0%
TTM-2,271.3%YOY-3,987.3%+1,716.0%
TTM-2,271.3%5Y-1,251.7%-1,019.6%
5Y-1,251.7%10Y-799.8%-451.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2,271.3%-298.0%-1,973.3%
TTM-2,271.3%-238.5%-2,032.8%
YOY-3,987.3%-288.4%-3,698.9%
5Y-1,251.7%-486.2%-765.5%
10Y-799.8%-628.4%-171.4%
1.2.2. Operating Ratio

Measures how efficient Skinbiotherapeutics is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 23.71 means that the operating costs are 23.71 for each 1 in net sales.

Let's take a look of the Operating Ratio trends of SkinBioTherapeutics PLC:

  • The MRQ is 23.713. The company is inefficient in keeping operating costs low. -1
  • The TTM is 23.713. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ23.713TTM23.7130.000
TTM23.713YOY40.873-17.160
TTM23.7135Y12.917+10.796
5Y12.91710Y8.373+4.544
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ23.7133.235+20.478
TTM23.7133.310+20.403
YOY40.8733.838+37.035
5Y12.9175.679+7.238
10Y8.3737.823+0.550

1.3. Liquidity of SkinBioTherapeutics PLC.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Skinbiotherapeutics is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.25 means the company has 3.25 in assets for each 1 in short-term debts.

Let's take a look of the Current Ratio trends of SkinBioTherapeutics PLC:

  • The MRQ is 3.248. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.248. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.248TTM3.2480.000
TTM3.248YOY4.583-1.335
TTM3.2485Y11.505-8.257
5Y11.50510Y14.603-3.098
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.2483.863-0.615
TTM3.2484.169-0.921
YOY4.5835.337-0.754
5Y11.5056.122+5.383
10Y14.6036.434+8.169
1.3.2. Quick Ratio

Measures if Skinbiotherapeutics is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Skinbiotherapeutics to the Biotechnology industry mean.
  • A Quick Ratio of 3.05 means the company can pay off 3.05 for each 1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of SkinBioTherapeutics PLC:

  • The MRQ is 3.052. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.052. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.052TTM3.0520.000
TTM3.052YOY4.192-1.140
TTM3.0525Y10.963-7.911
5Y10.96310Y13.251-2.288
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.0523.504-0.452
TTM3.0523.991-0.939
YOY4.1925.371-1.179
5Y10.9636.088+4.875
10Y13.2516.395+6.856

1.4. Solvency of SkinBioTherapeutics PLC.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Skinbiotherapeutics assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Skinbiotherapeutics to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.23 means that Skinbiotherapeutics assets are financed with 23.1% credit (debt) and the remaining percentage (100% - 23.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of SkinBioTherapeutics PLC:

  • The MRQ is 0.231. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.231. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.231TTM0.2310.000
TTM0.231YOY0.198+0.033
TTM0.2315Y0.132+0.099
5Y0.13210Y0.103+0.029
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2310.339-0.108
TTM0.2310.337-0.106
YOY0.1980.271-0.073
5Y0.1320.368-0.236
10Y0.1030.388-0.285
1.4.2. Debt to Equity Ratio

Measures if Skinbiotherapeutics is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Skinbiotherapeutics to the Biotechnology industry mean.
  • A Debt to Equity ratio of 30.0% means that company has 0.30 debt for each 1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of SkinBioTherapeutics PLC:

  • The MRQ is 0.300. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.300. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.300TTM0.3000.000
TTM0.300YOY0.246+0.054
TTM0.3005Y0.160+0.140
5Y0.16010Y0.122+0.038
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3000.392-0.092
TTM0.3000.403-0.103
YOY0.2460.335-0.089
5Y0.1600.427-0.267
10Y0.1220.461-0.339

2. Market Valuation of SkinBioTherapeutics PLC

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every 1 in earnings Skinbiotherapeutics generates.

  • Above 15 is considered overpriced but always compare Skinbiotherapeutics to the Biotechnology industry mean.
  • A PE ratio of -8.50 means the investor is paying -8.50 for every 1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of SkinBioTherapeutics PLC:

  • The EOD is -6.290. Based on the earnings, the company is expensive. -2
  • The MRQ is -8.500. Based on the earnings, the company is expensive. -2
  • The TTM is -8.500. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-6.290MRQ-8.500+2.210
MRQ-8.500TTM-8.5000.000
TTM-8.500YOY-15.452+6.952
TTM-8.5005Y-32.996+24.496
5Y-32.99610Y-28.469-4.527
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-6.290-2.300-3.990
MRQ-8.500-2.656-5.844
TTM-8.500-2.718-5.782
YOY-15.452-4.145-11.307
5Y-32.996-6.258-26.738
10Y-28.469-6.315-22.154
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of SkinBioTherapeutics PLC:

  • The EOD is -6.346. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -8.575. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -8.575. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-6.346MRQ-8.575+2.230
MRQ-8.575TTM-8.5750.000
TTM-8.575YOY-14.095+5.520
TTM-8.5755Y-31.204+22.629
5Y-31.20410Y-27.685-3.519
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-6.346-2.974-3.372
MRQ-8.575-3.306-5.269
TTM-8.575-3.508-5.067
YOY-14.095-5.613-8.482
5Y-31.204-8.378-22.826
10Y-27.685-8.873-18.812
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Skinbiotherapeutics is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 12.08 means the investor is paying 12.08 for each 1 in book value.

Let's take a look of the Price to Book Ratio trends of SkinBioTherapeutics PLC:

  • The EOD is 8.940. Based on the equity, the company is overpriced. -1
  • The MRQ is 12.080. Based on the equity, the company is expensive. -2
  • The TTM is 12.080. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD8.940MRQ12.080-3.141
MRQ12.080TTM12.0800.000
TTM12.080YOY15.772-3.691
TTM12.0805Y14.967-2.887
5Y14.96710Y10.932+4.036
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD8.9401.914+7.026
MRQ12.0802.116+9.964
TTM12.0802.097+9.983
YOY15.7722.881+12.891
5Y14.9673.550+11.417
10Y10.9323.936+6.996
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of SkinBioTherapeutics PLC compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.249-0.2490%-1.421+470%-0.150-40%0.129-293%
Book Value Per Share--1.0351.0350%1.284-19%1.656-38%1.556-34%
Current Ratio--3.2483.2480%4.583-29%11.505-72%14.603-78%
Debt To Asset Ratio--0.2310.2310%0.198+17%0.132+75%0.103+124%
Debt To Equity Ratio--0.3000.3000%0.246+22%0.160+87%0.122+146%
Dividend Per Share----0%-0%-0%-0%
Eps---1.471-1.4710%-1.311-11%-0.980-33%-0.709-52%
Free Cash Flow Per Share---1.458-1.4580%-1.437-1%-1.007-31%-0.723-50%
Free Cash Flow To Equity Per Share---0.256-0.2560%-1.455+469%-0.045-83%0.278-192%
Gross Profit Margin--1.0291.0290%1.016+1%1.009+2%1.006+2%
Intrinsic Value_10Y_max---18.224--------
Intrinsic Value_10Y_min---21.011--------
Intrinsic Value_1Y_max---1.187--------
Intrinsic Value_1Y_min---1.483--------
Intrinsic Value_3Y_max---4.053--------
Intrinsic Value_3Y_min---5.021--------
Intrinsic Value_5Y_max---7.506--------
Intrinsic Value_5Y_min---9.152--------
Market Cap1783363000.000-35%2409950000.0002409950000.0000%3904119000.000-38%5142833300.000-53%3801696125.000-37%
Net Profit Margin---21.469-21.4690%-37.354+74%-11.765-45%-7.528-65%
Operating Margin---22.713-22.7130%-39.873+76%-12.517-45%-7.998-65%
Operating Ratio--23.71323.7130%40.873-42%12.917+84%8.373+183%
Pb Ratio8.940-35%12.08012.0800%15.772-23%14.967-19%10.932+11%
Pe Ratio-6.290+26%-8.500-8.5000%-15.452+82%-32.996+288%-28.469+235%
Price Per Share9.250-35%12.50012.5000%20.250-38%26.675-53%19.719-37%
Price To Free Cash Flow Ratio-6.346+26%-8.575-8.5750%-14.095+64%-31.204+264%-27.685+223%
Price To Total Gains Ratio-37.119+26%-50.160-50.1600%-14.249-72%12.002-518%4.222-1288%
Quick Ratio--3.0523.0520%4.192-27%10.963-72%13.251-77%
Return On Assets---1.093-1.0930%-0.905-17%-0.616-44%-0.434-60%
Return On Equity---1.421-1.4210%-1.128-21%-0.747-47%-0.518-64%
Total Gains Per Share---0.249-0.2490%-1.421+470%-0.150-40%0.129-293%
Usd Book Value--2485857.3512485857.3510%3084547.342-19%3977929.267-38%3739213.236-34%
Usd Book Value Change Per Share---0.003-0.0030%-0.018+470%-0.002-40%0.002-293%
Usd Book Value Per Share--0.0130.0130%0.016-19%0.021-38%0.019-34%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.018-0.0180%-0.016-11%-0.012-33%-0.009-52%
Usd Free Cash Flow---3502054.393-3502054.3930%-3451502.608-1%-2420286.821-31%-1737005.768-50%
Usd Free Cash Flow Per Share---0.018-0.0180%-0.018-1%-0.013-31%-0.009-50%
Usd Free Cash Flow To Equity Per Share---0.003-0.0030%-0.018+469%-0.001-83%0.003-192%
Usd Market Cap22222486.343-35%30030386.95030030386.9500%48649226.859-38%64084845.751-53%47372935.414-37%
Usd Price Per Share0.115-35%0.1560.1560%0.252-38%0.332-53%0.246-37%
Usd Profit---3532879.169-3532879.1690%-3479860.106-2%-2419651.560-32%-1744968.035-51%
Usd Revenue--164556.228164556.2280%93159.682+77%51543.182+219%32645.795+404%
Usd Total Gains Per Share---0.003-0.0030%-0.018+470%-0.002-40%0.002-293%
 EOD+3 -5MRQTTM+0 -0YOY+13 -215Y+4 -3010Y+3 -31

3.2. Fundamental Score

Let's check the fundamental score of SkinBioTherapeutics PLC based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-6.290
Price to Book Ratio (EOD)Between0-18.940
Net Profit Margin (MRQ)Greater than0-21.469
Operating Margin (MRQ)Greater than0-22.713
Quick Ratio (MRQ)Greater than13.052
Current Ratio (MRQ)Greater than13.248
Debt to Asset Ratio (MRQ)Less than10.231
Debt to Equity Ratio (MRQ)Less than10.300
Return on Equity (MRQ)Greater than0.15-1.421
Return on Assets (MRQ)Greater than0.05-1.093
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of SkinBioTherapeutics PLC based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5045.080
Ma 20Greater thanMa 5010.106
Ma 50Greater thanMa 1009.422
Ma 100Greater thanMa 20012.050
OpenGreater thanClose9.250
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2023-06-30. Currency in GBP. All numbers in thousands.

Summary
Total Assets2,594
Total Liabilities599
Total Stockholder Equity1,995
 As reported
Total Liabilities 599
Total Stockholder Equity+ 1,995
Total Assets = 2,594

Assets

Total Assets2,594
Total Current Assets1,721
Long-term Assets873
Total Current Assets
Cash And Cash Equivalents 1,312
Net Receivables 305
Inventory 33
Other Current Assets 71
Total Current Assets  (as reported)1,721
Total Current Assets  (calculated)1,721
+/-0
Long-term Assets
Property Plant Equipment 173
Intangible Assets 700
Long-term Assets  (as reported)873
Long-term Assets  (calculated)873
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities530
Long-term Liabilities70
Total Stockholder Equity1,995
Total Current Liabilities
Short-term Debt 31
Accounts payable 194
Other Current Liabilities 304
Total Current Liabilities  (as reported)530
Total Current Liabilities  (calculated)530
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt70
Long-term Liabilities  (as reported)70
Long-term Liabilities  (calculated)70
+/-0
Total Stockholder Equity
Common Stock1,731
Retained Earnings -11,123
Accumulated Other Comprehensive Income 439
Other Stockholders Equity 10,948
Total Stockholder Equity (as reported)1,995
Total Stockholder Equity (calculated)1,995
+/-0
Other
Capital Stock1,731
Cash and Short Term Investments 1,312
Common Stock Shares Outstanding 164,713
Liabilities and Stockholders Equity 2,594
Net Debt -1,211
Net Invested Capital 1,995
Net Working Capital 1,191
Property Plant and Equipment Gross 259
Short Long Term Debt Total 101



Balance Sheet

Currency in GBP. All numbers in thousands.

 Trend2023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-30
> Total Assets 
423
4,332
3,650
3,931
2,771
5,735
3,085
2,594
2,5943,0855,7352,7713,9313,6504,332423
   > Total Current Assets 
287
4,117
3,363
3,578
2,348
5,063
2,333
1,721
1,7212,3335,0632,3483,5783,3634,117287
       Cash And Cash Equivalents 
257
3,923
3,183
3,125
2,159
4,610
1,805
1,312
1,3121,8054,6102,1593,1253,1833,923257
       Net Receivables 
30
154
153
286
141
213
328
305
30532821314128615315430
       Other Current Assets 
0
194
180
453
48
239
77
71
7177239484531801940
   > Long-term Assets 
136
215
288
354
422
672
752
873
873752672422354288215136
       Property Plant Equipment 
0
0
0
7
2
143
127
173
17312714327000
       Intangible Assets 
136
215
288
347
421
529
626
700
700626529421347288215136
       Other Assets 
0
0
0
0
0
0
0
0
00000000
> Total Liabilities 
34
119
209
121
305
520
610
599
59961052030512120911934
   > Total Current Liabilities 
34
119
209
121
305
405
509
530
53050940530512120911934
       Short-term Debt 
0
0
0
0
0
25
27
31
31272500000
       Accounts payable 
28
85
209
121
139
79
73
194
19473791391212098528
       Other Current Liabilities 
0
33
77
62
166
380
377
304
3043773801666277330
   > Long-term Liabilities 
0
0
131
121
305
115
101
70
7010111530512113100
> Total Stockholder Equity
390
4,214
3,441
3,810
2,466
5,215
2,475
1,995
1,9952,4755,2152,4663,8103,4414,214390
   Common Stock
1
1,187
1,187
1,281
1,281
1,568
1,568
1,731
1,7311,5681,5681,2811,2811,1871,1871
   Retained Earnings Total Equity00000000
   Accumulated Other Comprehensive Income 
0
0
0
-3
403
385
437
439
439437385403-3000
   Capital Surplus 
0
3,578
3,578
4,924
4,924
8,758
0
0
008,7584,9244,9243,5783,5780
   Treasury Stock00000000
   Other Stockholders Equity 
0
3,676
3,748
1,361
4,924
8,758
8,758
10,948
10,9488,7588,7584,9241,3613,7483,6760



Balance Sheet

Currency in GBP. All numbers in thousands.




Cash Flow

Currency in GBP. All numbers in thousands.




Income Statement

Currency in GBP. All numbers in thousands.


Latest Income Statement (annual, 2023-06-30)

Gross Profit (+$)
totalRevenue132
Cost of Revenue-90
Gross Profit4242
 
Operating Income (+$)
Gross Profit42
Operating Expense-3,041
Operating Income-2,999-2,999
 
Operating Expense (+$)
Research Development931
Selling General Administrative37
Selling And Marketing Expenses81
Operating Expense3,0411,049
 
Net Interest Income (+$)
Interest Income0
Interest Expense-9
Other Finance Cost-0
Net Interest Income-9
 
Pretax Income (+$)
Operating Income-2,999
Net Interest Income-9
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-3,008-2,991
EBIT - interestExpense = -3,008
-3,008
-2,826
Interest Expense9
Earnings Before Interest and Taxes (EBIT)-2,999-2,999
Earnings Before Interest and Taxes (EBITDA)-2,955
 
After tax Income (+$)
Income Before Tax-3,008
Tax Provision--174
Net Income From Continuing Ops-2,834-2,834
Net Income-2,835
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses3,131
Total Other Income/Expenses Net-99
 

Technical Analysis of Skinbiotherapeutics
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Skinbiotherapeutics. The general trend of Skinbiotherapeutics is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Skinbiotherapeutics's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of SkinBioTherapeutics PLC.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 13.00 < 14.00 < 14.00.

The bearish price targets are: 9 > 9 > 7.

Tweet this
SkinBioTherapeutics PLC Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of SkinBioTherapeutics PLC. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

SkinBioTherapeutics PLC Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of SkinBioTherapeutics PLC. The current macd is -0.10671279.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Skinbiotherapeutics price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Skinbiotherapeutics. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Skinbiotherapeutics price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
SkinBioTherapeutics PLC Daily Moving Average Convergence/Divergence (MACD) ChartSkinBioTherapeutics PLC Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of SkinBioTherapeutics PLC. The current adx is 17.35.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Skinbiotherapeutics shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
SkinBioTherapeutics PLC Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of SkinBioTherapeutics PLC. The current sar is 13.08.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
SkinBioTherapeutics PLC Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of SkinBioTherapeutics PLC. The current rsi is 45.08. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -3/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
SkinBioTherapeutics PLC Daily Relative Strength Index (RSI) ChartSkinBioTherapeutics PLC Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of SkinBioTherapeutics PLC. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Skinbiotherapeutics price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
SkinBioTherapeutics PLC Daily Stochastic Oscillator ChartSkinBioTherapeutics PLC Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of SkinBioTherapeutics PLC. The current cci is -78.1039425.

SkinBioTherapeutics PLC Daily Commodity Channel Index (CCI) ChartSkinBioTherapeutics PLC Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of SkinBioTherapeutics PLC. The current cmo is -17.95599053.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
SkinBioTherapeutics PLC Daily Chande Momentum Oscillator (CMO) ChartSkinBioTherapeutics PLC Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of SkinBioTherapeutics PLC. The current willr is -83.33333333.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
SkinBioTherapeutics PLC Daily Williams %R ChartSkinBioTherapeutics PLC Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of SkinBioTherapeutics PLC.

SkinBioTherapeutics PLC Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of SkinBioTherapeutics PLC. The current atr is 0.82563529.

SkinBioTherapeutics PLC Daily Average True Range (ATR) ChartSkinBioTherapeutics PLC Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of SkinBioTherapeutics PLC. The current obv is 180,315.

SkinBioTherapeutics PLC Daily On-Balance Volume (OBV) ChartSkinBioTherapeutics PLC Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of SkinBioTherapeutics PLC. The current mfi is 28.65.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
SkinBioTherapeutics PLC Daily Money Flow Index (MFI) ChartSkinBioTherapeutics PLC Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for SkinBioTherapeutics PLC.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-19STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-28SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-03SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-09CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-23CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-24CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-26MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-31STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-08MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-19STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-22STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-23BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-04SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-18WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-19CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-27ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-28MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-02RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-03ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-04MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-05MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-09SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-11CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-17WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-23STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

SkinBioTherapeutics PLC Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of SkinBioTherapeutics PLC based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5045.080
Ma 20Greater thanMa 5010.106
Ma 50Greater thanMa 1009.422
Ma 100Greater thanMa 20012.050
OpenGreater thanClose9.250
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Skinbiotherapeutics with someone you think should read this too:
  • Are you bullish or bearish on Skinbiotherapeutics? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Skinbiotherapeutics? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about SkinBioTherapeutics PLC

I send you an email if I find something interesting about SkinBioTherapeutics PLC.


Comments

How you think about this?

Leave a comment

Stay informed about SkinBioTherapeutics PLC.

Receive notifications about SkinBioTherapeutics PLC in your mailbox!